Corticosteroid Taper Schedule Calculator

Corticosteroid tapering is dictated by the hypothalamic-pituitary-adrenal axis rather than by the disease being treated. Exogenous glucocorticoid above roughly 5 to 7.5 mg of prednisone equivalent per day exceeds normal daily cortisol output of about 5 to 10 mg, and sustained excess suppresses hypothalamic CRH and pituitary ACTH release until the adrenal zona fasciculata atrophies. A taper therefore has to be slow enough for that axis to reawaken. Dose steps are proportionally larger at the top of the schedule, around 10 mg above 40 mg prednisone equivalent, and shrink to 1 to 2.5 mg near physiologic replacement, where the patient becomes dependent on their own cortisol. Conversion between agents uses anti-inflammatory potency: 5 mg prednisone equals 4 mg methylprednisolone, 0.75 mg dexamethasone, or 20 mg hydrocortisone. Practitioners generally regard courses shorter than 2 to 3 weeks as not requiring any taper, while 20 mg or more of prednisone equivalent for 3 weeks or longer carries a high probability of axis suppression. Recovery is assessed with an early morning serum cortisol, where a value above 10 micrograms/dL is reassuring and below 3 suggests continued insufficiency, or with a 250 microgram cosyntropin stimulation test. Full recovery can take 6 to 12 months. The main limitation of any calculated schedule is that it is arithmetic, not physiologic: it cannot distinguish relapse of the underlying disease from glucocorticoid withdrawal syndrome, and it does not adjust for stress dosing during surgery or intercurrent illness.

The compound at the center of every taper was isolated at the Mayo Clinic by Edward Kendall in the 1930s and independently characterized by Tadeus Reichstein in Basel. In September 1948 Philip Hench injected Kendall compound E, later named cortisone, into a woman with severe rheumatoid arthritis, and her dramatic improvement launched steroid therapy worldwide. Hench, Kendall and Reichstein shared the 1950 Nobel Prize in Physiology or Medicine. Enthusiasm faded quickly as Cushingoid features, infection and, most dangerously, circulatory collapse after stopping treatment appeared in the early 1950s, when reports described fatal adrenal crisis in patients whose cortisone had been discontinued before surgery. Synthetic analogues followed rapidly. Prednisone and prednisolone reached the market in 1955 with roughly four times the anti-inflammatory potency of cortisone and less sodium retention, and dexamethasone arrived in 1958 with far longer biological action. The quantitative basis for slow withdrawal came from work such as the 1965 study by Graber, Ney, Nicholson, Island and Liddle, which followed patients after long-term steroid suppression and showed that plasma ACTH recovers before adrenal cortisol responsiveness, with normal function returning only after roughly nine months. That sequential recovery model, together with equivalence tables for the newer analogues, is what modern taper schedules encode.